The 4th Fc-Mediated Function Summit 2024 was held in Boston, MA from April 17-18, and focused on discussions supercharging FcRn, FcγR, and IgG to advance molecular development, clinical utility, and novel therapeutic applications. During the event, industry experts from across the globe gathered to share the latest research in Fc biology insights, including:
Translating Fc Biology Insights to Innovate Drug Design
Fc Receptor Role in IO Drug Development to Transfer in Autoimmunity
Developing Antibody Target Engagement & Fc-Mediated Function
Targeting FcγR - What is the Next Mutation?
Biointron Summary Report:
1. Innovative Drug Design
Understanding Fc biology, effector functions, and inhibitors to discover opportunities to improve antibody therapeutics.
Using Fc Factor 8 to activate NK cells for specific targeting of unwanted B-cells.
Showcase of mouse models expressing human Fc receptors as tools for translational assessment of Fc receptor-targeted therapies.
2. Autoimmunity
Systemic IgA may be exploited for potential novel therapeutics strategies against infectious disease.
Next generation formats like tetravalent bispecific antibodies in the Fc are beneficial for cancer immunotherapy.
The combination of checkpoint blocking and Fc-mediated tumor cell killing can lead to novel cancer therapeutics.
3. Fc-Mediated Functions
Engineered antibody and albumin molecules with tailored binding and transport properties was discussed.
Evaluation of the main Fc silencing mutations, and what specific needs there are is useful for enhancing diesign optimization.
4. Targeting FcγR
Using the potential of Fc gamma receptors to tune antibody-based immunotherapy with tailored FcgR-blockade.
PD-1 agonist antibodies rely on the mediated clustering of FcγRs to trigger their sppresive function.
Thank you to everyone who visited our booth at the 4th Fc-Mediated Function Summit 2024 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.
Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.
ScientistとScience Exchangeとのご利用可能です。
